Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effects of Postoperative Pain Management on Immune Function After Laparoscopic Resection of Colorectal Cancer

This study has been completed.
Information provided by (Responsible Party):
So Yeon Kim, Severance Hospital Identifier:
First received: December 7, 2013
Last updated: January 10, 2016
Last verified: January 2016
The purpose of this study is to compare postoperative immune function (e.g. NK cell activity) of fentanyl-based analgesic regimen versus local anesthetic wound infiltration-based anlagesic regimen after laparoscopic colorectal surgery

Condition Intervention
Colorectal Surgery
Drug: fentanyl-based analgesia
Drug: local anesthetic wound infiltration-based anlagesia

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by So Yeon Kim, Severance Hospital:

Primary Outcome Measures:
  • NK cell activity [ Time Frame: 48 hours ]
    NK cell activity : preoperation, POD 1, POD 2

  • IL-2 [ Time Frame: 48 hours ]
    IL-2 level : preoperation, POD 1, POD 2

Secondary Outcome Measures:
  • Complication and recurrence [ Time Frame: 1 year ]
    Postoperative complication, recurrence

Other Outcome Measures:
  • Inflammatory responses [ Time Frame: 48 hours ]
    White blood cell, neutrophil, C-reactive protein (CRP) : preoperation, POD 1, POD 2

Enrollment: 60
Study Start Date: January 2014
Study Completion Date: December 2015
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: fentanyl-based analgesia
fentanyl intravenous patient-controlled analgesia + additional pethidine
Drug: fentanyl-based analgesia
fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour
Experimental: local anesthetic wound infiltration-based anlagesia
continuous wound inflitration with ropivacaine + tramadol intravenous patient-controlled analgesia + additional ketorolac or propacetamol
Drug: local anesthetic wound infiltration-based anlagesia
continuous wound inflitration with ropivacaine + tramadol patient-controlled analgesia + additional ketorolac or propacetamol for postoperative 48 hour


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ASA class I-III
  • 20-80 years old
  • elective laparoscopic colorectal surgery for cancer

Exclusion Criteria:

  • drug allergy
  • significant renal or hepatic impairment
  • sign of infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02012244

Korea, Republic of
Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine
Sedoul, Korea, Republic of
Sponsors and Collaborators
Severance Hospital
  More Information

Responsible Party: So Yeon Kim, Assistant professor, Severance Hospital Identifier: NCT02012244     History of Changes
Other Study ID Numbers: 4-2013-0044
Study First Received: December 7, 2013
Last Updated: January 10, 2016

Keywords provided by So Yeon Kim, Severance Hospital:
analgesia; colorectal surgery; immunity; local anesthetics; opioids

Additional relevant MeSH terms:
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Opioid
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General processed this record on May 25, 2017